Results 91 to 100 of about 40,867 (262)

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. [PDF]

, 2017
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density.
Aubry-Rozier, B., Birkhäuser, M., Bischoff-Ferrari, H.A., Ferrari, S., Frey, D., Kressig, R.W., Lamy, O., Lippuner, K., Meier, C., Stute, P., Suhm, N., Uebelhart, B.   +11 more
core   +4 more sources

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain [PDF]

, 2015
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in ...
Darbà, Josep, Kaskens, Lisette, Lothgren, Mickael, Sorio Vilela, Francesc   +3 more
core   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer, 2019
Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF).
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi, Toshimi Takano   +15 more
doaj   +1 more source

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

International Journal of Endocrinology, 2020
Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been
Chaiho Jeong, Hee-Je Kim, Seok Lee, Moo Il Kang, Jeonghoon Ha   +4 more
doaj   +1 more source

Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Long-term care issues, specifically metabolic bone disorders, are a concern for people living with human immunodeficiency virus (PLWH) who undergo life-long antiretroviral therapy (ART).
Yusuke Kunimoto, Ryosuke Matamura, Hiroshi Ikeda, Hiroto Horiguchi, Satoshi Fujii, Masayoshi Kobune, Masahide Fukudo, Takaki Toda   +7 more
doaj   +1 more source

a case report and review of the literature [PDF]

, 2013
PublishedN/
Aragon-Ching, Jeanny B., El-Amm, Joelle, Freeman, Ashley   +2 more
core   +1 more source

Vascular Calcification: Mechanisms, Models, and Therapies

iNew Medicine, EarlyView.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu, Shu Yang, Ziyi Chen, Xiaoxiao Yang, Zhen Liang, Yuanli Chen   +5 more
wiley   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source